Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

348 results about "Biosynthetic genes" patented technology

DFR, LDOX/ANS and UFGTs are the major LBGs (downstream structural genes) of the anthocyanin biosynthetic pathway. DFR (dihydroflavonol-4-reductase) catalyzes the first committed reaction to generate anthocyanins. In A. thaliana, the gene AtDFR is known to encode a functional DFR [24].

Live bacterial vaccines resistant to carbon dioxide (CO2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment

The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO2, acid pH, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced TNF-α induction having a mutation in one or more lipid biosynthesis genes, including, but not limited to msbB, that are rendered stress-resistant by a mutation in the zwf gene. The present invention provides compositions comprising one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. In particular, the present invention relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. The present invention further relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants as vectors for the delivery of one or more therapeutic molecules. The methods of the invention provide more efficient delivery of therapeutic molecules by stress-resistant gram-negative bacterial mutants engineered to express said therapeutic molecules.
Owner:AVIEX TECH

Live bacterial vaccines resistant to carbon dioxide (CO2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment

The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO2, acid pH, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced TNF-α induction having a mutation in one or more lipid biosynthesis genes, including, but not limited to msbB, that are rendered stress-resistant by a mutation in the zwf gene. The present invention provides compositions comprising one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. In particular, the present invention relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. The present invention further relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants as vectors for the delivery of one or more therapeutic molecules. The methods of the invention provide more efficient delivery of therapeutic molecules by stress-resistant gram-negative bacterial mutants engineered to express said therapeutic molecules.
Owner:AVIEX TECH

Biosynthesis gene cluster of polyenoid and polyol macrolide compound

The invention discloses cloning, sequencing, analysis, function study and application of a biosynthesis gene cluster of a novel anti-microbial and anti-tumor compound WSS2277 in the field of biotechnologies. The gene cluster comprises nucleotide sequences of twenty-one genes or complementary sequences which are formed by the sequences 1, wherein the fourteen genes including siaA, siaB1, siaB2, siaC, siaD, siaE, siaF, siaG, siaH, siaI, siaJ, siaK, siaL and siaM are responsible for the synthesis of a carbon skeleton, and the seven genes incluidng siaN, siaO, siaP, siaQ, siaR, siaS and siaT are responsible for regulating biosynthesis. The information of the genes which are related to the biosynthesis of the WSS2277 is provided by the invention, and a foundation is provided for the study and the genetic modification of the biosynthesis of the WSS2277. A novel structural analogue can be generated through the modification of carbon skeleton synthesis genes in the WSS2277, and the yield of the WSS2277 or a derivative thereof can be provided through the interruption or the high replication of regulator genes in the WSS2277. The genes and proteins, which are provided by the invention, can also be used for searching and discovering compounds or genes and proteins, which can be applied to the fields of medicine, industry or agriculture.
Owner:SICHUAN INDAL INST OF ANTIBIOTICS CHINA NAT PHARMA GROUP CORP

High-yield engineering bacterium of nicomycin x component and its application

InactiveCN1548526ABacteriaFermentationStreptomyces ansochromogenesMultiple cloning site
The present invention belongs to the field of antibiotic gene engineering, and is especially the process of cloning nicomycin biological synthetic gene sanU from one strain of Streptomyces ansochromogenes 7100 CGMCC 4.321; connecting the synthetic gene sanU with promoter of melanin biosynthetic structure gene, cloning onto the polycloning site of integrative single-copy plamid, transforming wild Streptomyces ansochromogenes 7100 CGMCC 4.321 protoplast to obtain nicomycin X component of the recombinant engineering bacterium in the yield 2 times higher than wild strain. The high-yield engineering bacterium may be used in preparing antiseptic medicines.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI

Indolocarbazole alkaloid with cytotoxic activity as well as preparation method and application

The invention provides indolocarbazole alkaloid with cytotoxic activity as well as a preparation method thereof, aiming at the problems which exist in indolocarbazole alkaloid in the prior art. The new indolocarbazole alkaloid is obtained through a recombination strain constructed by adopting a biotechnological means and directional transformation carried out on an STA biosynthesized gene clusterspc, thereby opening up a new thought for combinatorial biosynthesis research of the indolocarbazole alkaloid. The indolocarbazole alkaloid with the cytotoxic activity has a good inhibiting effect onall cancer cell strains; compared with STA, the toxicity of the indolocarbazole alkaloid to human normal hepatocyte LO2 is greatly reduced, so that the indolocarbazole alkaloid has potential for developing a medicine for treating diseases relevant to protein kinase. In addition, the method provided by the invention is easy to operate and implement, can be used for realizing industrialized mass production, and has a broad application prospect and tremendous commercial value.
Owner:OCEAN UNIV OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products